Intervention

Abemaciclib

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 116 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials116

Recruiting35

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI TrialNCT07191717 · 2026-05-18

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast CancerNCT07112053 · 2025-11-17

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerNCT07100106 · 2025-10-07

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast CancerNCT06678269 · 2024-11-15

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorNCT05933395 · 2024-09-23

RADIANT: Pre-op Radiation With Abemaciclib and LetrozoleNCT06139107 · 2024-08-22

Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerNCT06409390 · 2024-08-14

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerNCT06179303 · 2024-07-22

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast CancerNCT06365788 · 2024-04-08

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)NCT06169371 · 2023-12-28

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsNCT06188520 · 2023-12-05

ETHAN - ET for Male BCNCT05501704 · 2023-10-11

Study of AVZO-021 in Patients With Advanced Solid TumorsNCT05867251 · 2023-08-30

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsNCT05372640 · 2023-08-10

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)NCT05891093 · 2023-06-01

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyNCT06805812 · 2023-05-01

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · 2023-04-17

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerNCT05735080 · 2023-03-28

VS-6766+Abema+Fulv in Met HR+/HER- BCNCT05608252 · 2023-02-23

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerNCT05573126 · 2023-01-11

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerNCT05386108 · 2022-08-31

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerNCT05524584 · 2022-08-31

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerNCT05113537 · 2022-07-08

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsNCT05307705 · 2022-05-11

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesNCT04923542 · 2021-11-30

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast CancerNCT04523857 · 2021-11-01

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaNCT04941274 · 2021-09-29

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast CancerNCT05095207 · 2021-09-20

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerNCT04802759 · 2021-06-22

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant AbemaciclibNCT04614194 · 2021-04-15

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.NCT04305834 · 2020-03-25

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerNCT03424005 · 2018-03-30

Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and AbemaciclibNCT07428018 · 2026-04-30

NOT_YET_RECRUITING

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerNCT06630325 · 2025-06-24

Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in EgyptNCT07487129 · 2024-08-25

Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular SubtypingNCT06561022 · 2024-08-21

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerNCT06495164 · 2024-06-24

ACTIVE_NOT_RECRUITING

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationNCT05708235 · 2024-04-01

ACTIVE_NOT_RECRUITING

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentNCT05999968 · 2024-01-12

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11

ACTIVE_NOT_RECRUITING

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05

ACTIVE_NOT_RECRUITING

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerNCT06001762 · 2023-10-05

ACTIVE_NOT_RECRUITING

Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerNCT05617885 · 2023-08-09

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid TumorsNCT05759949 · 2023-03-29

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)NCT05548127 · 2023-02-23

ACTIVE_NOT_RECRUITING

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerNCT05563220 · 2023-01-24

ACTIVE_NOT_RECRUITING

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCNCT05766410 · 2022-09-16

Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With PalbociclibNCT05464173 · 2022-07-01

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast CancerNCT04791384 · 2022-04-21

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)NCT05288166 · 2022-04-14

ACTIVE_NOT_RECRUITING

Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.NCT05789771 · 2022-04-01

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerNCT05169567 · 2022-03-11

ACTIVE_NOT_RECRUITING

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast CancerNCT04316169 · 2021-10-21

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerNCT04975308 · 2021-10-04

ACTIVE_NOT_RECRUITING

Abemaciclib With or Without Atezolizumab for mCRPCNCT04751929 · 2021-08-20

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)NCT04964934 · 2021-06-30

ACTIVE_NOT_RECRUITING

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast CancerNCT04481113 · 2021-06-07

Common conditions

Leading sponsors

Eli Lilly and Company 36 AstraZeneca 5 Dana-Farber Cancer Institute 4 Hoffmann-La Roche 4 National Cancer Institute (NCI) 3 OHSU Knight Cancer Institute 3 Blokhin's Russian Cancer Research Center 2 Fudan University 2 H. Lee Moffitt Cancer Center and Research Institute 2 MedSIR 2 Novartis Pharmaceuticals 2 Pfizer 2 Stemline Therapeutics, Inc. 2 University of California, Irvine 2 University of Washington 2

Trial status mix

RECRUITING35

COMPLETED29

ACTIVE_NOT_RECRUITING26

TERMINATED14

WITHDRAWN5

UNKNOWN4

APPROVED_FOR_MARKETING2

NOT_YET_RECRUITING1

Phase mix

PHASE260

PHASE144

PHASE320

PHASE45

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.